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Background: The association between Hashimoto’s thyroiditis (HT) and papillary thyroid carcinoma (PTC) is a
controversial question that is still under debate, its pathological significance and the eventual clinical implications of
this association remaining unclear.
Methods: The data regarding 305 patients were retrospectively analyzed. The patients were divided in two
different groups. A first group made up of 142 patients undergoing surgery for differentiated thyroid carcinoma
was compared to a control group of 142 analogous subjects operated for normofunctioning goiter. A second
group was made up of 163 patients who had undergone total thyroidectomy (TT) with pre-operative diagnosis of
HT.
Results: In the first group of patients an association with HT was found in 28,6% of the patients with final
histopathological diagnosis of PTC versus 7,7% of the patients with histopathological diagnosis of multinodular
goiter, which was a significant difference (p < 0.001). In the second group, the association with PTC was found in
43 (40,2%) cases of HT nodular variant and in 3 cases (8,1%) of HT diffuse variant (p < 0.001).
Conclusions: The relationship between HT and PTC is still far from clear and represents an unresolved issue. Our
own study has underlined the frequent coexistence of these two pathologies, an aspect not to be neglected in
clinical practice. Patients receiving HT diagnosis should undergo careful follow-up and, especially those with the
nodular variant, should undergo a frequent both clinical and cytological evaluation of the nodular lesions, taking
always into great consideration the surgical approach of total thyroidectomy.
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Hashimoto’s thyroiditis (HT) is the most common auto-
immune inflammatory pathology of the thyroid and is the
main cause of autoimmune hypothyroidism. It is charac-
terized by an infiltrate of immune cells able to determine
the destruction of the gland, its fibrous involution and
consequent hypothyroidism [1–3]. It was first described
by Hakaru Hashimoto in 1912 as “lymphomatous struma”
[4]. Global occurrence of HT is estimated between 0.3 and
1.5 cases out of 1000 individuals per year, prevalently* Correspondence: calogero.cipolla@unipa.it
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and 50 years of age [5–7].
There are two different clinical variants: the diffuse
form and the nodular form. The nodular form is domi-
nated by a non-homogeneous thyroid parenchyma that
presents fibrosis, sclerosis and calcifications and is the
one primarily associated with neoplastic formations,
papillary carcinoma of the thyroid in particular. Treat-
ment is almost always medical, surgery is indicated in in-
crease glandular volume with compressive symptoms, in
unsatisfactory drug therapy and in suspicious of neoplas-
tic degeneration of one or more nodules.
The link between HT and papillary carcinoma of the
thyroid (PTC), first described by Dailey et al. in 1955 [5],le is distributed under the terms of the Creative Commons Attribution 4.0
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was subject of numerous studies, there isn’t a unani-
mous scientific literature opinion and the medical debate
is still open.
The primary outcome of this study was try to clarify if
this link exists and how important it is. The secondary
outcome was to identify its possible clinical, diagnostic
and therapeutic implication.Methods
After approval by the institutional review board at Univer-
sity Hospital AUOP Paolo Giaccone of Palermo, a retro-
spective analysis of the medical records of a series of 305
consecutive patients was conducted. The patients were se-
lected among 2175 undergone total thyroidectomy (TT)
in the period from January 2006 to December 2016. All
patients with preoperative diagnosis of both thyroid car-
cinoma and of Hashimoto’s thyroiditis were considered
eligible for the study. Two hundred fifty-eight patients
(84,6%) were females, 47 (15,4%) were male with 1/5M/F
ratio. The mean age was of 50,6 years (range 13–82). The
305 patients were divided in two different groups.
The first group (Group 1) consisted of 142 patients
underwent TT for a TIR 5 preoperative fine-needle aspir-
ation cytological diagnosis; the second group (Group 2)
consisted of 163 patients underwent TT for a preoperative
diagnosis of HT. The first group of patients was compared
to a control group matched for sex and gender, consisting
of 142 patients who had undergone surgical intervention
during the same period involving total thyroidectomy for
normal functioning multi-nodular goiter.
In all cases the preoperative diagnostic plan included
thyroid hormones assay, thyroid ultrasonography, thyroid
scintigraphy, and ultrasound-guided cytological examin-
ation using fine needle aspiration biopsy (FNAB). The
diagnosis of HT was based on an increase in serum values
of anti peroxidase and antithyroglobulin antibodies.
The Italian consensus to classify thyroid cytology has
provided a standardized reporting scheme, including the
subdivision of indeterminate for malignancy TIR-3 cat-
egory into TIR-3A (low-risk) and TIR-3B (high-risk) [8].
The histopathological diagnosis of HT was based on
the presence of diffuse, chronic, inflammatory infiltrate,
mainly composed of T-lymphocytes and plasma cells or-
ganized in germinative centers, but also due to the pres-
ence of fibrotic areas, which did not extend beyond the
capsule, as well as to the presence of atrophic follicles
with numerous Hürthle cells and enlarged thyroid cells,
characterized by abundant cytoplasm, which was eosino-
phil and rich in mitochondria.
ASA score ≤ III, age less than 82 years old, HT diagno-
sis, TIR5 preoperative cytological diagnosis and a
complete clinical, laboratory and radiological evaluationwere the main surgical inclusion criteria. All patients
underwent total thyroidectomy.
Statistical analysis was performed by X2 test, with
Yates’ correction where appropriate, a P value of less
than 0.5 indicated statistical significance.
Results
Group 1
The 74,6% of all patients enrolled in this group were
women (106 patients) with 1/3M/F ratio; the mean age
was of 50,2 years (range 13–82 years). PTC was con-
firmed at histological examination in 126 patients
(88,7%); follicular carcinoma was diagnosed in 8 cases
(5,6%), medullary carcinoma in 2 cases (1,4%), an onco-
cytic variant was found in 5 cases (3,5%) while 1 case
(0,7%) was an insular variant.
This group of patients was compared to an analogous
group matched for sex and gender composed of 142 pa-
tients who underwent surgical intervention during the
same period involving TT for normal functioning multi-
nodular goiter.
Of the142 patients who had undergone TT for thyroid
carcinoma, in 36 cases thyroid histological examination
showed the concomitant presence of a chronic lympho-
cytic thyroiditis to be attributed to HT. The link was
found exclusively in the 126 cases with histological diag-
nosis of PTC with an incidence rate of association be-
tween PTC and HT equal to 28,6%. In 3 cases (2,3%),
PTC was found in association with Graves’s disease and
with hyper-functioning multi-nodular goiter. In the
remaining cases, PTC either presented as a single nodule
in a healthy gland or was associated with a histopath-
ology of normal functioning multinodular goiter. Al-
though, in the control group, the concomitant presence
of a histopathology compatible with HT was found only
in 11 cases (7,7%).
The association between PTC and HT has proved to
be widely significant (p < 0.001) compared with that ob-
served in patients who had undergone surgery for multi-
nodular goiter (Table 1).
Group 2
The 93,2% of 163 patients were female (152 patients), 11
were male; the M/F ratio was of 1:14. The mean age was
of 50,6 years (range 20–82 years). One hundred and
seven cases (65,4%) were nodular variant of HT, 37 cases
(22,7%) were diffuse variant of HT, in 19 cases (11,7%)
HT had developed in patients during follow-up proce-
dures for normal functioning multinodular goiter.
In HT nodular variant, 42 of 107 patients (39,2%)
underwent surgical approach for a TIR 3B or TIR 4 pre-
operative cytological diagnosis, 53 cases (49,5%) because
of a volumetric increase of one or more nodules, in 12
cases (11,2%) for the onset of local neck symptoms.
Table 1 Papillary thyroid carcinoma coexistent with Hashimoto’s thyroiditis (Group 1)
PTC (126 patients) Multinodular goiter (142 patients)
Mean age 51,3 yrs (range 27–71 yrs) 50,9 yrs (range 30–71 yrs) NS
Sex:
Male 30 32 NS
Female 96 110
M/F ratio 1/3 1/3
Euthyroid 126 (100%) 142 (100%) NS
Coexistent HT 36/126 patients 28,6% 11/142 patients 7,7% P < 0.001
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tients with HT resulting from previous goiter underwent
surgical approach due to a volumetric increase of the
gland, associated with a compressive symptoms.
Of the 163 patients who underwent TT with preopera-
tive diagnosis of HT, in 51 cases (31,3%) at histopatho-
logical examination a differentiated thyroid carcinoma
was found. In 47 cases (92,2%) it was PTC, in 3 cases
(5,9%) follicular carcinoma and just in one case (1,9%)
mucous-epidermoid carcinoma. A PTC was co-existent
in 43 out of 107 cases (40,2%) of nodular variant HT, in
3 out 37 cases (8,1%) of diffuse variant HT and in 1 of
19 cases (5,2%) of HT which had developed on a previ-
ous goiter.
The average diameter of the tumours, established at
histopathological examination, was of 10,6 mm (range:
0,2–20,6 mm) in 13 cases of PTC it was a question of
microcarcinoma, including those 3 cases associated with
diffuse variant HT, where the diameter of the PTC was
≤5mm. In no case were found lymph nodes involvement
or presence of distant metastasis. Among the remaining
112 patients with preoperative diagnosis of HT, in 13
cases (7,9%) an association with micro- and/or macrofol-
licular adenoma was present, 32 cases (19,6%) were asso-
ciated with diffuse goiter and 44 cases (26,9%) with a
normal functioning multinodular goiter. In the
remaining 23 cases (14,1%) HT was not associated with
any other pathology.
It is important to underline that 43 out of the 47 cases
of PTC (91,5%) were found in patients with nodular
variant HT compared with other forms of thyroiditisTable 2 Hashimoto’s thyroiditis coexistent with Papillary thyroid car
HT
Nodular variant
Coexistent PTC 43/107 patients 40,2%
Coexistent HT and PTC
Mean age 47,5 yrs
M/F ratio 1:12
Time laps between HT
diagnosis and surgery
29.7 m(p < 0.001), indicating a significantly higher risk of the
PTC development on the nodular variant of HT.
The sex and age of patients nor the time lapse occur-
ring between the diagnosis of HT and surgery seemed to
be at significant at all. In fact, in the group of 47 patients
with an association between HT and PTC, the male/fe-
male ratio was 1:12 and the mean age was 47,5 years,
while in the 116 patients in whom HT was not associ-
ated with PTC, the male/female ratio was 2:22 and the
mean age was 49,7 years. In patients who underwent sur-
gery for HT associated with PTC, the HT diagnosis had
been made on average 29,7 months before surgery
(range: 0–96months), whereas in patients with HT not
associated with PTC, the diagnosis of HT had been
made on average 31,3 months before surgery (range: 0–
113 months) (Table 2).
Discussion
The association of HT with PTC has remained an active
focus of research and controversy since it was first de-
scribed in the 50’s. The aim of our study was to verify
the association between HT and PTC by evaluating two
groups of patients who underwent surgery at our insti-
tute between 2006 and 2016. In the first group, we com-
pared the different histopathological pictures indicating
HT found in patients undergoing surgery for thyroid car-
cinoma and in a control group involving patients who
had undergone surgery for normal functioning goiter. In
the second group of patients, we evaluated the incidence
of PTC found in patients receiving surgery after a
pre-operative diagnosis of HT. A significant associationcinoma (Group 2)
HT
Diffuse variant
3/37patients 8,1% P < 0.001
HT
49,7 yrs NS
2:22 NS
31.3 m NS
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tients. In fact, in the first group of studied patients, a
histological picture matching with HT was observed in
28,6% of cases undergoing surgery for PTC as opposed
to the 7,7% of cases undergoing surgery for nodular goi-
ter. In the second group of studied patients, in 31,3% of
cases undergoing surgery for HT, the coexistence with
PTC was revealed and in almost all cases it was a nodu-
lar variant of HT.
These findings, which confirm what reported in our
own earlier study published in 2005 [9], are in agree-
ment with various studies published in the literature
[10–12] and, albeit indirectly, they suggest the presence
of a link between the two pathologies, even though the
true nature of such link is till today, topic of much dis-
cussion and debate.
The debate focuses particularly on the possible role of
HT as a risk factor in the development of PTC or, alter-
natively, on its eventual role of defense against neoplasia
and therefore as a factor for favorable prognosis.
Virchow had already hypothesized the presence of a
pathogenetic link between inflammation and neoplastic
degeneration in 1863. A study by Chui et al. [13] dem-
onstrated that the follicular epithelium of the thyroid in
the context of autoimmune thyreopathy is not homoge-
neous and that chronically present phlogistic infiltrates
may in fact be responsible for the dysplastic transform-
ation of the follicular epithelium. This would lead to the
formation of so-called “zones of follicular displasia”,
areas characterized by intense proliferation of follicular
cells which present high concentrations of TG, TTF-1,
HBM1, galectine3 and CK-19, even though the typical
characteristics of papillary carcinoma are not present.
This is a pre-neoplastic lesion, which can easily complete
its evolution towards the form of PTC. This result con-
firms what was reported by other authors, who have
found that the incidence rate of carcinoma in patients
with HT range between 0.5 and 53% and it is much
higher than that in patients without HT [14–16]. More-
over, in about 90% of HT cases the expression of the
mutation of oncogenes RET/PTC, typical of PTC, was
found in quantities that easily overlap between the two
forms of pathologies [17–19].
At the same time, the expression of protein p63 ap-
pears to have a role in the correlation between HT and
PTC. Unger et al. [20] had demonstrated that the ex-
pression of protein p63 appears to be greatly superior in
patients with HT and PTC compared to those with a
healthy thyroid, or with nodular goiter or follicular
adenomas.
According to more recent studies, the coexistence of
HT and PTC seems to find a further explanation in the
conspicuous production of cytokines, which character-
izes HT. These cytokines, whose number increases withphlogosis, would regulate the activation of pathways fun-
damental to neoplastic growth such as angiogenesis, cel-
lular proliferation and the inhibition of apoptosis. In this
respect, TNFα, the endothelial growth factor (VEGF),
the nitric oxide produced by macrophages and the
HMGB-1 protein seem to be the most involved cyto-
kines [21–23].
Further new studies aim at underlying the importance
of HT as a favorable factor in the prognosis of subjects
with PTC. The coexistence of HT and PTC appears to
be associated to clinical-pathological characteristics of
reduced tumor aggressiveness and with diminished re-
currence of the pathology [24–28]. Lun et al. [29] had
produced a case-controlled study on 2478 patients who
underwent TT. If compared with a group of patients
with multi-nodular goiter, patients with PTC presented
greater coexistence of HT; moreover, patients with HT
associated PTC were younger, female, with smaller tu-
mors and, in general, with a less advanced stage of TNM
compared to those who had PTC without HT.
An effective prognosis for patients with PTC coexistent
with HT is an important point when reflecting on the
pathogenetic link between these two pathologies. It is well
known that innate immune response constitutes the first
mechanism of defense against agents, which would attack
the organism, including tumor cells. Tumor cells are able
to trigger both innate and non-innate immune response
that could be responsible for the development of auto-
immune phenomena leading to a completely new mech-
anism, that of autoimmunity due to an anti-neoplastic
immune response.
The study conducted by Kari et al. [30] on mice
models susceptible to thyroid disease supports this the-
ory, showing how genetic predisposition to autoimmune
thyroid disease may favor the appearance of an auto-
immune response during an immune response to the
tumor. This mechanism of autoimmunity associated to
antitumor immune response appears to reveal itself in
other studies too, such as in those aimed at analyzing
the association between antitumoural immunotherapy
and autoimmunity [31, 32].
The autoimmune response within the context of an
antitumor immune response would be confirmed by the
presence of anti-TG (AAT) and anti-TPO (ATPO) anti-
bodies in about 20% of patients with thyroid carcinoma,
with values twice higher in patients with PTC, compared
to the general population [33]. The development of
autoantibodies might be part of a more complex defense
mechanism against tumors with the objective of elimin-
ating the precursors of future neoplastic cells [34].
The reasons for an antitumor immune response might
be found in the existence of papillary thyroid microcarci-
noma which has not yet been diagnosed. This small neo-
plasia would be able to induce an antitumor immune
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mote the cross-reactivity and consequent epitope-specific
autoimmune-response.
Conclusions
In conclusion, the relationship between HT and PTC is
still far from clear and represents an unanswered ques-
tion particularly concerning the physiopathological and
clinical mechanisms linking these two pathologies. Our
own study has underlined the frequent coexistence of
these two pathologies, and, unlike previous studies, it
corroborates the most recent theories according to
which the link between HT and PTC may be due to the
presence of an autoimmune-response which develops
along with an antitumoural immune-response. Never-
theless, further studies will be necessary, in order to
comprehend the true nature of the link existing between
the two pathologies.
In any case, regardless of how numerous the question
marks may be, we cannot ignore the elevated rates of in-
cidence of PTC in patients with HT. Accordingly, pa-
tients receiving HT diagnosis should undergo careful
follow-up with periodical evaluation of thyroid hor-
mones and autoantibodies and special attention paid to
TSH and AAT. Especially those patients with the nodu-
lar variant should undergo both clinical and cytological
evaluation of the nodular lesions. Moreover, given the
greater risk of developing PTC (1.6 times greater), an ad-
equate therapeutic planning should be in force for pa-
tients with nodular variant HT. The use of L4-Thyroxine
has proved excellent in suppressing TSH and in redu-
cing the risk of PTC. However, in certain conditions, es-
pecially in cases in which the indications noted above
reach elevated concentrations, the surgical approach of
TT must be given serious consideration.
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